Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus nab-paclitaxel for unresectable gallbladder cancer (phase II, single-arm)
ChiCTR2200055698Phase 2Recruiting
- Sponsor
- Xinhua Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in gallbladder cancer, sponsored by Xinhua Hospital. Primary endpoint: Objective Response Rate. Started Oct 2021; status: recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2200055698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055698.